Reuters logo
7 months ago
RPT-BRIEF-Exelixis and Ipsen amend exclusive licensing agreement for commercialization,development of Cabozantinib to include Canada
December 21, 2016 / 6:13 AM / 7 months ago

RPT-BRIEF-Exelixis and Ipsen amend exclusive licensing agreement for commercialization,development of Cabozantinib to include Canada

1 Min Read

Dec 21 (Reuters) - Exelixis Inc

* Press release - Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include canada

* Exelixis - Amendment enhances productive year with Cabometyx regulatory approvals and commercial launches in United States and European Union

* Says Exelixis to receive $10 million upfront payment, with subsequent regulatory and commercial milestones

* Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of Cabozantinib to include Canada

* Says Ipsen is currently initiating launch of Cabometyx in EU

* Says regulatory filing in canada is expected in 2017, with regulatory approval anticipated in early 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below